Trending >

Spectral Diagnostics spikes on EUPHRATES trial expansion

Shares of Spectral Diagnostics (TSX:SDI) are up today after the company announced that the Data Safety Board had increased the sample size of its EUPHRATES trial from 360 to 650 patients.

“We are pleased with the positive outcome of the second interim analysis,” said CEO Dr. Paul Walker. “The enthusiasm and support from our clinical trial sites has been outstanding. Based on current enrolment rates and number of sites, we anticipate completion of the trial in the first half of 2016.”

Etobicoke’s Spectral Diagnostics focuses on treatments for Sepsis, otherwise known as blood poisoning. The company feels the effects of the disease, which affects about a million people each year in the United States alone, can be seriously improved with better, faster diagnostic testing.

Spectral’s EAA™ (Endotoxin Activity Assay) is the only FDA cleared, CE marked rapid diagnostic for endotoxemia. The treatment received clearance in 2003. The company belives the combination of EAA and Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream and is used in the EUPHRATES trial, could prove to be a more effective treatment.

At press time, shares of Spectral Diagnostics were up 18% to $0.36.


We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

About The Author /

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.
insta twitter facebook


Leave a Reply